gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

Biochemical recurrence (bREC) and survival in patients with conformal radiation therapy (CRT) for prostate cancer

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Hans Geinitz - Klinik für Strahlentherapie der Technischen Universität München, Deutschland
  • Frank Zimmermann - Klinik für Strahlentherapie der Technischen Universität München
  • Reinhard Thamm - Klinik für Strahlentherapie der Technischen Universität München
  • Tobias Müller - Klinik für Strahlentherapie der Technischen Universität München
  • Kerstin Jess - Klinik für Strahlentherapie der Technischen Universität München
  • Caroline Erber - Klinik für Strahlentherapie der Technischen Universität München
  • Raymonde Busch - Institut für Medizinische Statistik der Technischen Universität München
  • Michael Molls - Klinik für Strahlentherapie der Technischen Universität München

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO310

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk420.shtml

Published: March 20, 2006

© 2006 Geinitz et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Purpose: To evaluate the incidence of bREC and its association with survival in patients who received definitive CRT for prostate cancer.

Material and Methods: 385 patients with localized prostate cancer (cN0M0) were retrospectively analyzed. T-stage: T1: 19%, T2: 57%, T3: 23%, T4: 1%. Grading: G1: 16%, G2: 72%, G3: 12 % G4: < 1%. Median initial PSA: 11.7 ng/ml. Median follow-up was 60 months (12-128 m.). The median dose to the prostate was 70 Gy (59-72 Gy), 78% of the patients received short term neoadjuvant hormonal therapy. Biochemical recurrence (bREC) was defined either as 3 consecutive PSA-rises (ASTRO) or as an increase of 2ng/ml above the current PSA-nadir (HOUSTON).

Results: Five-year biochemical free survival (bNED) was 69% (ASTRO) and 77% (HOUSTON), respectively. The overall- and disease specific survival was 87% and 99% at 5 years, respectively. The 5-year incidence of local recurrence and distant metastasis was 3% and 4%, respectively. In multivariate analysis the following variables were significantly associated with bNED: ASTRO: initial PSA (p<0.001), grading (p=0.005), T-stage (p=0.020); HOUSTON: initial PSA (p<0.001), grading (p=0.001), PSA nadir after CRT (p=0.008). Univariately bREC (ASTRO or HOUSTON) significantly correlated with local recurrence, distant metastasis and disease specific survival but not with overall survival. In multivariate analysis bREC (ASTRO or HOUSTON) was associated with local recurrence and distant metastasis but only bREC HOUSTON correlated with disease specific survival.

Conclusions: Initial PSA and WHO-grading are closely associated with bNED. bREC is a negative predictor for local recurrence, distant metastasis and disease specific survival but -after a median follow-up of five years- it is not associated with overall survival. bREC HOUSTON seems to better predict disease specific survival than bREC ASTRO.